admin – Page 5349 – Get News Story

Hypeal.com and TA-DAAN Introduce a Cutting-Edge VIP Membership Program on Shopify’s App Store.

The Prime Experience for Shopify Brands

Amsterdam – September 24th, 2024 – Hypeal.com is excited to announce the launch of TA-DAAN’s VIP Memberships, a groundbreaking loyalty program set to transform customer engagement and boost sales for Shopify brands. This innovative program, now available on the Shopify App Store, offers a range of exclusive benefits tailored to enhance the shopping experience and foster brand loyalty.

Introducing TA-DAAN’s VIP Membership: For just €29 per year, TA-DAAN’s VIP Membership provides customers with unparalleled value and access to a host of exclusive benefits:

15% Instant Discount: Enjoy an immediate 15% off your cart when you add the TA-DAAN VIP Membership to your order.

10% OFF for One Year: Receive a 10% discount on all future orders for an entire year (up to a maximum of 20% off).

Free Shipping: Benefit from free shipping on orders over €150.

Early Access: Get early access to limited edition products.

Exclusive Events: Attend members-only events and experiences.

TA-DAAN’s VIP Membership is a testament to Hypeal’s commitment to reshaping the e-commerce landscape by providing brands with the tools they need to offer compelling, value-driven loyalty programs. Learn more about the membership here.

About TA-DAAN:

TA-DAAN is an innovative startup founded in 2020 by Roberta Ligossi, Sara Pianori, Costanza Tomba, and Valeria Zanirato, with the aim of promoting, supporting, and actively empower the new generation of artisans and therefore contemporary craftsmanship, through a content e-commerce, and the creation of editorial and digital content on various social platforms, as well as offline and online experiential events. Among TA-DAAN’s cornerstones: creativity, uniqueness, and awareness.

Hypeal:

Empowering E-commerce Brands Hypeal.com is a B2B SaaS tech startup empowering e-commerce brands to launch their VIP membership programs, unlocking recurring revenue for the brands and exclusive experiences for members through Hypeal™ gating technology, using blockchain. Since August 2023, Hypeal has raised $200,000 from ABN AMRO and Techstars. The team, led by Forbes 30 Under 30 honoree in Retail and E-commerce 2024, has a proven track record of success in the e-commerce industry.

Join the Revolution:

Experience the future of e-commerce loyalty programs with Hypeal and TA-DAAN’s VIP Memberships. Discover how these programs can boost your Average Order Value (AOV), increase purchase frequency, and generate new revenue streams.For more information and to get started, visit Hypeal on the Shopify App Store.

About Hypeal:

Hypeal.com is at the forefront of e-commerce innovation, offering unique loyalty solutions that drive customer engagement and brand loyalty. Our mission is to replace third-party ad dependency with first-party data sharing, rewarding shoppers for their brand loyalty and creating a seamless shopping experience.

Media Contact
Company Name: Hypeal.com
Contact Person: Ta-Daan Marta Delpiano
Email: Send Email
Country: Netherlands
Website: https://hypeal.com/

Eightco Holdings Inc. Is Ripe For Appreciation After Scoring Q3 Milestone (NASDAQ: OCTO)

Investing really isn’t that difficult. Do some research, find untapped value in a company disrupting sector landscapes, and capitalize on that open window of opportunity. Completing the first two measures leads to a company like Eightco Holdings Inc. (NASDAQ: OCTO). Then, by taking that third action, especially while OCTO is still relatively under-the-radar of many, investors may find themselves positioned to maximize ROI from a ground-floor entry point. But know this: while the window of opportunity is open, don’t expect the bargain price to last.

In fact, the near-term path of least resistance for OCTO shares looks paved higher after the company reached a key Q3 milestone by regaining NASDAQ listing compliance. This accomplishment is more than just a regulatory win; it’s a powerful affirmation of OCTO’s financial resilience and strategic vision. By the way, the company did more than meet the minimums required to regain compliance; they crushed them by exceeding stockholders’ equity requirement by a substantial margin, reporting $13.4 million in equity, well above the $2.5 million threshold. Additionally, the closing bid price of its common stock remained above $1.00 for 20 consecutive trading days, doubling the minimum.

In addition to restoring investor confidence, the listing strengthens the foundation for OCTO to pursue its aggressive growth strategy, unhindered by past financial constraints. In fact, a much stronger and NASDAQ-listed OCTO now has untethered access to capital markets, institutional interest and support, and open doors to top-tier resources that can expedite steepening its revenue curve, drop more net income to its bottom line, and enhance shareholder value. Its NASDAQ listing wasn’t the only milestone reached this year.

A milestone-rich 2024

So far in 2024, OCTO has significantly improved its balance sheet, eliminated $5.4 million in convertible notes, and canceled over $23 million in liabilities. These actions not only pave a consistent path toward net income but also underscore OCTO’s commitment to financial discipline. The company’s work is already paying off, with OCTO reporting a net income of $4.4 million in Q2, a significant improvement over the ($8.9) million net loss in the prior year’s same quarter. This turnaround was not a coincidence of good fortune but a result of better operating performance, elimination of warrant losses, and margin increases. Regarding the latter, OCTO’s gross profit margin more than doubled, surging to 25.3%, up from 12.3% in the previous year. The company also slashed SG&A expenses by 26.6%. These financial improvements are not just numbers—they are the tangible results of a company reshaping its future that points to a new era of profitability.

With that in mind, growth stock investors may want to seize this opportunity sooner rather than later. Plenty supports doing so, including a book value calculation supporting an OCTO stock price of over $7.00. However, an increase to book value of over 228% from its current $2.13 share price may only be a rest stop and not a final destination, especially when factoring in strategic decisions and actions that have accelerated OCTO’s mission to deliver a great Q4 and even better 2025. Turning an ambitious mission into dollars is more than likely, it’s probable, especially with its main wholly owned subsidiary, Forever 8 Fund LLC is emerging as a player in the rapidly expanding e-commerce and refurbished electronics markets.

A valuable and revenue-generating subsidiary

Forever 8 provides an innovative inventory financing solution for small and mid-sized e-commerce businesses. Its model is particularly timely given the current e-commerce climate, where managing cash flow and maintaining adequate inventory levels often challenge sellers. Forever 8 addresses this problem by purchasing inventory on its client’s behalf. This allows them to allocate capital toward marketing, customer acquisition, and expanding product lines rather than tying it up in inventory. The innovative solution quickly alleviates the cash flow burden that often stifles brand growth, making it easier for sellers to scale their operations.

What makes Forever 8’s model especially compelling, and in demand, is its proprietary, data-driven tool that accurately assesses inventory risk. By leveraging historical sales data, demand trends, and other relevant factors, Forever 8 can make informed decisions about which products to stock and in what quantities. This predictive capability ensures efficient capital deployment and minimizes risk, creating value for both Forever 8 and its clients. The platform’s integration of inventory planning, purchasing, and payouts further simplifies the complex process of inventory management, enabling e-commerce sellers to scale with confidence and reduce their exposure to supply chain uncertainties.

Forever 8’s strategic venture into the refurbished Apple (NASDAQ: AAPL) products market further differentiates Forever 8 from other players in the e-commerce space. With consumer demand for cost-effective, high-quality electronics on the rise, particularly for refurbished Apple products like iPhones, iPads, and Apple Watches, this interest presents a significant growth opportunity. The rising popularity of refurbished electronics is driven by affordability and a shift toward eco-conscious consumerism, which values sustainable alternatives. By facilitating the resale of Apple products through major platforms like Amazon (NASDAQ: AMZN) and Shopify (NASDAQ: SHOP), Forever 8 taps into this growing market segment while aligning with broader sustainability trends.

Moreover, this expansion diversifies the company’s revenue streams and positions Forever 8 to capitalize on the burgeoning circular economy. By the way, Forever 8 is no newbie to the markets. As of July 2024, it crossed $100 million of Iphone sales. In other words, OCTO isn’t hoping to penetrate markets and exploit a major market opportunity- they already are.

A value proposition exposed

Expect them to continue seizing its opportunities. Based on its updates, Eightco remains focused on building on recent successes, prioritizing growing revenues. Now that OCTO has regained compliance for NASDAQ, that could happen faster than many may expect, especially as new doors open to assist in securing additional growth capital to energize its core business operations.

Noting OCTO’s impressive gross margins and demand in the refurbished electronics market surging, utilizing fresh capital could lead to a beat of optimistic forecasts. In other words, one of the next headlines in the queue could give investors a double dose of what drives share prices higher- top and bottom line growth. If so, with only about 1.78 million shares outstanding, it’s a fair assumption that the OCTO share price may react favorably. Considering the laws of supply and demand in market situations, perhaps exponentially so.

Disclaimers: This is sponsored content. Hawk Point Media Group, Llc. (HPM) has been compensated by Interactive Offers to produce and distribute digital content for Eightco Holdings, Inc. It should be expressly understood that HPM is not operated by a licensed broker, a dealer, or a registered investment adviser. It should also be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. HPM reports/releases are commercial advertisements and are for general information purposes ONLY. The information made available by HPM is not intended to be, nor does it constitute, investment advice or recommendations. The contributors do NOT buy and sell securities covered before or after any particular article, report and/or publication. HPM holds ZERO shares and has never owned stock in Eightco Holdings, Inc. While HPM does not own or market shares, it is prudent to expect that those hiring HPM including that company’s owners, employees, and affiliates, may sell some or even all of the Eightco Holdings, Inc. shares that they own, if any, during and/or after this engagement period. Always do your own due diligence prior to investing in any publicly traded company. For a full disclaimer and disclosure statement, click HERE.

Media Contact
Company Name: Hawk Point Media
Contact Person: Editorial Dept.
Email: info@hawkpointmedia.com
Country: United States
Website: https://hawkpointmedia.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Eightco Holdings Inc. Is Ripe For Appreciation After Scoring Q3 Milestone (NASDAQ: OCTO)

Deep Vein Thrombosis Market Statistics Expected to Experience Major Growth by 2032, According to DelveInsight | Bayer, LEO Pharma, Agen Biomedical, MinaPharm Pharma, GlaxoSmithKline, Pfizer

Key Deep Vein Thrombosis Companies in the market include – Bayer, LEO Pharma, Agen Biomedical, Bristol-Myers Squibb, Sanofi, Ottawa Hospital Research Institute, Daiichi Sankyo, MinaPharm Pharmaceuticals, GlaxoSmithKline, Pfizer, Anthos Therapeutics, Inc., and others.

DelveInsight’s “Deep Vein Thrombosis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Deep Vein Thrombosis, historical and forecasted epidemiology as well as the Deep Vein Thrombosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of Deep Vein Thrombosis, offering comprehensive insights into the Deep Vein Thrombosis revenue trends, prevalence, and treatment landscape. The report delves into key Deep Vein Thrombosis statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Deep Vein Thrombosis therapies. Additionally, we cover the landscape of Deep Vein Thrombosis clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Deep Vein Thrombosis treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Deep Vein Thrombosis space.

To Know in detail about the Deep Vein Thrombosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Deep Vein Thrombosis Market Forecast

Some of the key facts of the Deep Vein Thrombosis Market Report:

The Deep Vein Thrombosis market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
Key Deep Vein Thrombosis Companies: Bayer, LEO Pharma, Agen Biomedical, Bristol-Myers Squibb, Sanofi, Ottawa Hospital Research Institute, Daiichi Sankyo, MinaPharm Pharmaceuticals, GlaxoSmithKline, Pfizer, Anthos Therapeutics, Inc., and others
Key Deep Vein Thrombosis Therapies: Rivaroxaban, innohep®, ThromboView, Apixaban, SanOrg34006, Tinzaparin, edoxaban tosylate, r-Hirudin, Fondaparinux sodium, PD 0348292, Dalteparin, and others
The Deep Vein Thrombosis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Deep Vein Thrombosis pipeline products will significantly revolutionize the Deep Vein Thrombosis market dynamics.
The Centers for Disease Control and Prevention (CDC) (2023) reports that while the exact number of individuals affected by DVT or PE is uncertain, it is estimated that up to 900,000 people may be impacted annually in the United States.
According to Waheed et al. (2023), over 200,000 individuals in the United States develop venous thrombosis each year, with 50,000 cases complicated by pulmonary embolism. The annual incidence of DVT is 80 cases per 100,000 people, with a prevalence of lower limb DVT at 1 case per 1,000 population.
Waheed et al. (2023) noted that deep vein thrombosis is uncommon in children, and the risk significantly rises with age, with most cases occurring in individuals over 40.
The CDC (2023) states that about 33% of individuals with DVT or PE will experience a recurrence within 10 years.

Deep Vein Thrombosis Overview

Deep vein thrombosis (DVT) is a condition where a blood clot forms in a deep vein, typically in the legs. This can cause pain, swelling, and discomfort. DVT is dangerous because the clot can break loose and travel to the lungs, leading to a life-threatening condition called pulmonary embolism. Risk factors include prolonged immobility, surgery, certain medications, and medical conditions that affect blood clotting. Treatment usually involves blood thinners to prevent clot growth and reduce the risk of complications. Early detection and treatment are critical to managing DVT effectively.

Get a Free sample for the Deep Vein Thrombosis Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/deep-vein-thrombosis-market

Deep Vein Thrombosis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Deep Vein Thrombosis Epidemiology Segmentation:

The Deep Vein Thrombosis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Total Prevalent Cases of DVT in the 7MM
Diagnosed Prevalent Cases of DVT in the 7MM
Age-specific Cases of DVT in the 7MM
Total Treated Cases of DVT in the 7MM

Download the report to understand which factors are driving Deep Vein Thrombosis epidemiology trends @ Deep Vein Thrombosis Epidemiology Forecast

Deep Vein Thrombosis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Deep Vein Thrombosis market or expected to get launched during the study period. The analysis covers Deep Vein Thrombosis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Deep Vein Thrombosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Deep Vein Thrombosis Therapies and Key Companies

Rivaroxaban: Bayer
innohep®: LEO Pharma
ThromboView: Agen Biomedical
Apixaban: Bristol-Myers Squibb
SanOrg34006: Sanofi
Tinzaparin: Ottawa Hospital Research Institute
edoxaban tosylate: Daiichi Sankyo
r-Hirudin: MinaPharm Pharmaceuticals
Fondaparinux sodium: GlaxoSmithKline
PD 0348292: Pfizer
Dalteparin: Anthos Therapeutics, Inc.

Discover more about therapies set to grab major Deep Vein Thrombosis market share @ Deep Vein Thrombosis Treatment Landscape

Deep Vein Thrombosis Market Strengths

The use of off-label branded and generic prescription medications targeted at individual symptoms of DVT.
Several academic institutions and pharmaceutical companies are currently conducting clinical trials for the treatment of various symptoms of DVT.

Deep Vein Thrombosis Market Opportunities

New therapeutic options are needed to address the unmet need for effective and curative therapies for DVT. This has created an opportunity for key players to develop novel therapies targeted towards this indication.

Scope of the Deep Vein Thrombosis Market Report

Study Period: 2019–2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Deep Vein Thrombosis Companies: Bayer, LEO Pharma, Agen Biomedical, Bristol-Myers Squibb, Sanofi, Ottawa Hospital Research Institute, Daiichi Sankyo, MinaPharm Pharmaceuticals, GlaxoSmithKline, Pfizer, Anthos Therapeutics, Inc., and others
Key Deep Vein Thrombosis Therapies: Rivaroxaban, innohep®, ThromboView, Apixaban, SanOrg34006, Tinzaparin, edoxaban tosylate, r-Hirudin, Fondaparinux sodium, PD 0348292, Dalteparin, and others
Deep Vein Thrombosis Therapeutic Assessment: Deep Vein Thrombosis current marketed and Deep Vein Thrombosis emerging therapies
Deep Vein Thrombosis Market Dynamics: Deep Vein Thrombosis market drivers and Deep Vein Thrombosis market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Deep Vein Thrombosis Unmet Needs, KOL’s views, Analyst’s views, Deep Vein Thrombosis Market Access and Reimbursement

To know more about Deep Vein Thrombosis companies working in the treatment market, visit @ Deep Vein Thrombosis Clinical Trials and Therapeutic Assessment

Table of Contents

1. Deep Vein Thrombosis Market Report Introduction

2. Executive Summary for Deep Vein Thrombosis

3. SWOT analysis of Deep Vein Thrombosis

4. Deep Vein Thrombosis Patient Share (%) Overview at a Glance

5. Deep Vein Thrombosis Market Overview at a Glance

6. Deep Vein Thrombosis Disease Background and Overview

7. Deep Vein Thrombosis Epidemiology and Patient Population

8. Country-Specific Patient Population of Deep Vein Thrombosis

9. Deep Vein Thrombosis Current Treatment and Medical Practices

10. Deep Vein Thrombosis Unmet Needs

11. Deep Vein Thrombosis Emerging Therapies

12. Deep Vein Thrombosis Market Outlook

13. Country-Wise Deep Vein Thrombosis Market Analysis (2019–2032)

14. Deep Vein Thrombosis Market Access and Reimbursement of Therapies

15. Deep Vein Thrombosis Market Drivers

16. Deep Vein Thrombosis Market Barriers

17. Deep Vein Thrombosis Appendix

18. Deep Vein Thrombosis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Deep Vein Thrombosis Market Statistics Expected to Experience Major Growth by 2032, According to DelveInsight | Bayer, LEO Pharma, Agen Biomedical, MinaPharm Pharma, GlaxoSmithKline, Pfizer

Alieus Hedge Fund Raises $1.5 Million in Just 15 Days

“Mr. Ashish Jain, Founder and CEO of Alieus Hedge Fund”

Alieus Hedge Fund Raises $1.5 Million in Just 15 Days Since Inception on 7th September 2024, Breaking All Records. Founder and CEO, Mr. Ashish Jain, Leads Groundbreaking Achievement.

London – 24 September, 2024 – Alieus Hedge Fund, India’s first hedge fund designed for the common man, has achieved a remarkable milestone by raising $1.5 million within just 15 days of its launch. This record-breaking success underscores the fund’s innovative approach and rapid acceptance in the market.

Under the leadership of Mr. Ashish Jain, Founder and CEO, Alieus Hedge Fund has quickly garnered attention for its mission to democratize hedge fund investing, making it accessible to a broader audience beyond traditional high-net-worth individuals. The fund’s unique model has clearly resonated with investors, leading to unprecedented growth in an incredibly short period.

Mr. Ashish Jain, Founder and CEO, shared his thoughts on the achievement:

“Raising $1.5 million in just 15 days is an extraordinary milestone that confirms the demand for more inclusive investment opportunities. At Alieus Hedge Fund, we are committed to breaking down financial barriers and providing everyday investors with access to strategies typically reserved for the elite. We are proud to have set a new record and look forward to continuing this momentum.”

Alieus Hedge Fund’s early success positions it as a game-changer in the financial industry, and the team is eager to build on this momentum by expanding its offerings and continuing to drive change in the hedge fund space.

Alieus Hedge Fund is the first hedge fund in India dedicated to making hedge fund investment opportunities available to the common man. By providing access to sophisticated financial strategies traditionally available only to high-net-worth individuals, the fund aims to democratize wealth creation.

For more information, please visit: www.alieusfund.com

Media Contact
Company Name: Alieus Hedge Fund
Contact Person: Ashish Jain
Email: Send Email
Country: United Kingdom
Website: www.alieusfund.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Alieus Hedge Fund Raises $1.5 Million in Just 15 Days

Silexion Therapeutics Reports Promising Phase 2 Data for Non-Resectable Pancreatic Cancer Treatment

Silexion’s (NASDAQ:SLXN) New analysis reveals improved resectability and response rates, providing hope for patients with one of the deadliest cancer types—and potentially much more.

Silexion Therapeutics (NASDAQ: SLXN), a clinical-stage biotech company developing cutting-edge RNA interference (RNAi) therapies, has announced compelling new findings from its Phase 2 trial of LODER™ in patients with non-resectable locally advanced pancreatic cancer (LAPC). The updated data shows a 56% objective response rate (ORR) and a 67% improvement in tumor resectability, a significant step forward in treating a cancer type that has long been resistant to effective intervention. But the implications of these findings may extend beyond pancreatic cancer, potentially impacting a much broader range of KRAS-driven cancers.

A Potential Turning Point in Pancreatic Cancer Treatment—And Beyond

Pancreatic cancer is among the most lethal forms of cancer, typically diagnosed at a late stage when treatment options are limited and often ineffective. For many patients, surgery is not an option due to the tumor’s location or the extent of its spread. The recent results from Silexion’s Phase 2 trial suggest that LODER™ could change this landscape by making previously inoperable tumors surgically treatable.

The trial targeted patients with KRAS G12D or G12V mutations, which are present in approximately 70% of pancreatic cancer cases. These mutations are notoriously difficult to treat, as conventional therapies struggle to effectively target these genetic drivers. Silexion’s LODER™ technology, however, uses a localized drug delivery system to deliver siRNA directly into the tumor, silencing the KRAS gene and preventing the production of cancer-promoting proteins. This approach not only tackles the underlying genetic issue but also offers a more targeted treatment option, minimizing damage to healthy tissues.

Beyond Pancreatic Cancer: The Broader Impact of KRAS Mutations

While pancreatic cancer is a critical focus, KRAS mutations play a role in many other aggressive cancers, including lung, colorectal, and ovarian cancers. In fact, KRAS is one of the most common oncogenes found in human cancers, especially in solid tumors. The challenge of effectively targeting KRAS mutations has been a major obstacle in oncology, as these mutations are often associated with resistance to standard therapies and poor patient outcomes.

This is where Silexion’s broader ambitions come into play. The company’s next-generation product, SIL-204, is designed to target a wider range of KRAS mutations, including those beyond the G12D/V mutations found in pancreatic cancer. By addressing multiple KRAS-driven cancers, SIL-204 could potentially transform treatment for a large number of patients who currently have limited therapeutic options.

Understanding the Clinical Trial Results

The Phase 2 trial, conducted in the U.S. and Israel, enrolled 48 patients with locally advanced pancreatic cancer that could not be surgically removed or tumors that were only marginally operable. The goal was to assess how effectively Silexion’s LODER™ technology could improve treatment outcomes for these patients.

To put it simply, the trial was divided into two groups. In the first group, 29 patients received either LODER™ combined with standard chemotherapy or chemotherapy alone. This helped researchers compare the overall survival rates between the two approaches. The second group consisted of 19 patients with tumors deemed inoperable, where the focus was on measuring how well the treatment worked and its safety.

The results were promising: 56% of patients with the targeted KRAS mutations responded positively to the treatment. Even more striking, 67% of tumors that were initially considered too complex for surgery shrank enough to become operable. This is a significant development because surgery remains the best chance for long-term survival in pancreatic cancer patients. By potentially turning previously inoperable tumors into candidates for surgery, LODER™ offers a new lifeline for those battling this deadly disease.

“We are very encouraged by these new findings, which demonstrate LODER’s ability to significantly improve tumor resectability in patients with non-resectable pancreatic cancer,” said Ilan Hadar, Chairman and CEO of Silexion. “As we advance our broader pipeline to address KRAS-driven cancers, this data further validates our oncogene silencing approach.”

The Broader Promise of SIL-204

Building on the success of LODER™, Silexion is also developing SIL-204, a next-generation siRNA therapy designed to target a broader range of KRAS mutations, including those that are currently beyond the reach of existing treatments. SIL-204 has shown promising preclinical results, demonstrating improved stability and enhanced delivery capabilities, which could make it more effective in silencing the KRAS gene.

The company plans to move SIL-204 into Phase 2/3 clinical trials in 2025-2026, aiming to establish its efficacy in not just pancreatic cancer, but a variety of KRAS-driven cancers. Given the high prevalence of KRAS mutations in many aggressive cancers, the potential impact of SIL-204 is enormous. This advancement could represent a major leap forward in the field of precision oncology, where effective treatment options for KRAS-driven cancers have long been limited.

Looking Ahead: A Unique Approach to a Complex Problem

Silexion’s RNAi technology stands out because it tackles the genetic drivers of cancer directly, rather than simply targeting the symptoms of the disease. By delivering treatment directly to the tumor site and silencing the KRAS gene at its source, Silexion’s approach has the potential to overcome some of the barriers that have historically limited progress in treating not just pancreatic cancer, but a wide array of KRAS-driven cancers.

As Silexion advances its clinical trials and explores the full potential of its RNAi technology, it may be poised to play a crucial role in the future of precision oncology. The recent new data from Phase 2 trials seem like a potentially promising sign that the company’s innovative approach could offer new hope to patients facing some of the most challenging cancers.

This update is for informational purposes only and is not intended to serve as financial, investment or any form of professional advice, recommendation or endorsement. Please review the full documentation detailing financial compensation disclosures and disclaimers the article is subject to. [https://justpaste.it/ab9dn/pdf]. Global Markets News Network is a commercial digital brand compensated to provide coverage of news and developments related to innovative companies as detailed in the full documentation and it is thus subject to conflicts of interest.

Media Contact
Company Name: Global Markets News Network
Contact Person: Editorial Desk
Email: Send Email
Country: Canada
Website: https://www.futuremarketsresearch.com/global-markets-news

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Silexion Therapeutics Reports Promising Phase 2 Data for Non-Resectable Pancreatic Cancer Treatment

Jackson Tree Service: Trusted Experts for Tree Service in Jackson, TN

“Tree Service in Jackson, TN | Jackson Tree Service”

With our tree service in Jackson, TN, we provide affordable services that are within your budget and also offer free estimates so that you can know the extent of the work we will undertake for you. At Jackson Tree Service, we pride ourselves in ensuring that every project is completed to the highest standard, ensuring that safety of our clients and their satisfaction is guaranteed.

Jackson, TN – Jackson Tree Service, your number one choice for any tree care services you may require. Whether it is an emergency tree removal, or a routine tree pruning, trimming or any other tree maintenance service, our professional team is dedicated to delivering the best services that will enhance the health and aesthetics of trees and your landscape.

Whether it’s an emergency tree removal in Jackson, TN or a regularly scheduled tree care service in Jackson, we have got you covered. Trees can become dangerous over the years because of a storm, diseases, or even the age of the tree, but when you have our team working for you, then you will know that your property is in good hands. To ensure that your home or business is safe and the value of your property is retained, we provide safe tree removal, stump grinding and pruning services.

Our experienced arborists not only aim at the removal of the dangerous trees but also working for the proper care of your current trees. Our tree services include a detailed evaluation of your trees to guarantee a healthy landscape all year. Jackson Tree Service is committed to providing sustainable tree services in Jackson since trees that are well maintained play a crucial role in the health of the environment and add beauty to the environment.

We also appreciate the need to have emergency tree removal services especially after storms have occurred. Our team is always on standby to act fast in order to remove any trees that have fallen or those that are damaged in order to avoid causing more harm to your property.

For reliable, professional tree care, contact Jackson Tree Service today at (731) 595-0626 or visit https://treeservicejacksontn.com/ to learn more.

Media Contact
Company Name: Jackson Tree Service
Email: Send Email
Phone: (731) 595-0626
City: Jackson
State: TN
Country: United States
Website: https://treeservicejacksontn.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Jackson Tree Service: Trusted Experts for Tree Service in Jackson, TN

Healthy Beginnings Wellness & Esthetics Center Offers Comprehensive Health & Wellness Services in Fredericksburg

Healthy Beginnings Wellness & Esthetics Center is a physician-directed, comprehensive health and wellness facility located in Fredericksburg, Virginia. The center is dedicated to offering personalized one-on-one care that educates clients on achieving and maintaining optimal weight management, personal improvement, and healthy lifestyles. With a commitment to enhancing overall well-being, Healthy Beginnings provides a broad spectrum of services tailored to meet the unique needs of each client.

Among the diverse offerings at Healthy Beginnings Wellness & Esthetics Center are hCG and phentermine weight loss programs, which are designed to assist clients in reaching and maintaining their ideal weight. In addition, the center provides BHRT, a natural approach to balancing hormones and alleviating symptoms associated with hormone imbalances, such as hot flashes, mood swings, and weight gain. For those looking to rejuvenate their appearance, the center offers Botox© and fillers, along with microneedling skin enhancement therapies, all of which are delivered by highly trained professionals.

The center also specializes in a range of injectable treatments, including B12/B Complex vitamin and amino acid injections, which are aimed at boosting energy levels and supporting overall health. IV therapy is another service provided, offering a quick and effective method for delivering essential nutrients directly into the bloodstream.

The medical team at Healthy Beginnings Wellness & Esthetics Center is composed of highly qualified professionals, including physicians, physician assistants, and nurses. This medically licensed personnel ensures that every client receives safe and effective care, whether the focus is on weight management, aesthetic enhancements, or general wellness.

Healthy Beginnings is particularly noted for its testosterone replacement therapy, which helps men experiencing symptoms of low testosterone, such as fatigue, weight gain, and decreased libido, regain their vitality and improve their quality of life. The center’s comprehensive approach also includes BHRT for women, designed to help them feel more energized, balanced, and vibrant.

Julie Belk-Dalberg, BSN, RN, the founder of Healthy Beginnings Wellness & Esthetics Center, emphasizes the center’s dedication to providing the highest quality care and personalized treatment plans. The team’s passion for helping clients achieve their health and wellness goals is evident in the supportive and caring environment they cultivate.

For individuals interested in exploring BHRT or other wellness services in Fredericksburg, Healthy Beginnings Wellness & Esthetics Center stands as a premier destination. The center’s focus on personalized care, combined with a comprehensive range of services, underscores its commitment to helping clients look and feel their best from the inside out.

To learn more about Healthy Beginnings Wellness & Esthetics Center or to schedule a consultation, visit their website at www.healthybeginningswellness.com or call (540) 656-2933.

Media Contact
Company Name: Healthy Beginnings Wellness & Esthetics Center
Contact Person: Julie Belk-Dalberg
Email: Send Email
Phone: +1 540-656-2933
Address:1185 Armory Dr Suite 200
City: Fredericksburg
State: VA 22401
Country: United States
Website: https://healthybeginningswellness.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Healthy Beginnings Wellness & Esthetics Center Offers Comprehensive Health & Wellness Services in Fredericksburg

Five Star Painting of Wexford Expands Services in Sewickley, Offering Premier Commercial and Residential Painting Solutions

Five Star Painting of Wexford is a trusted provider of professional painting services specializing in both residential and commercial projects. Known for exceptional quality and attention to detail, the company serves the Wexford area with a commitment to customer satisfaction, offering interior and exterior painting solutions that transform spaces beautifully and efficiently.

WEXFORD, PA – Five Star Painting of Wexford is proud to announce expanding its professional painting services to the Sewickley area. With a commitment to delivering top-tier quality and unmatched customer satisfaction, the company now offers a wide range of commercial and residential painting services tailored to the unique needs of businesses and homeowners in the community.

Businesses in Sewickley can now benefit from Commercial Painting Sewickley. Five Star Painting of Wexford offers solutions designed to enhance the look and feel of any commercial space. Whether a large office building or a boutique storefront, the expert team ensures precision and efficiency in every project, helping businesses maintain a professional and inviting atmosphere.

In addition to commercial services, residents can take advantage of expert Interior Painting Sewickley. Five Star Painting of Wexford pays homeowners meticulous attention to detail, transforming interior spaces into beautiful, refreshed environments. The team’s skilled painters work diligently to ensure high-quality results, using premium materials to guarantee a lasting finish.

For those seeking exterior transformations, Five Star Painting of Wexford also offers exceptional Exterior Painting Sewickley. Whether revitalizing a home’s curb appeal or ensuring the protection of a building’s exterior, the company delivers superior craftsmanship that stands the test of time.

About Five Star Painting of Wexford

With a strong reputation for reliability and excellence, Five Star Painting of Wexford is the go-to choice for both commercial and residential painting needs in Sewickley. More information can be found at Five Star Painting of Wexford.

Media Contact
Company Name: Five Star Painting of Wexford
Contact Person: Trey Harper
Email: Send Email
Phone: (412) 896-7343
City: Sewickley
State: PA
Country: United States
Website: https://www.fivestarpainting.com/wexford

Gifts by Sapna Wins the 2024 Quality Business Award for The Best Gift Shop in Bradford, UK

“Storefront Photograph”

Bradford, UK – September 24, 2024 – Gifts by Sapna has received the 2024 Quality Business Award for The Best Gift Shop in Bradford, UK. This accolade acknowledges Gifts by Sapna for its exceptional customer service, high-quality products and services, and overall business performance.

The Quality Business Awards annually acknowledges businesses exhibiting excellence within their industry. Selections are determined by taking into account their reputation, feedback from customers, and overall performance within their respective industries.

Gifts by Sapna is a leading gift shop in Bradford. This family business has incredible customer service. The lovely team at Gifts by Sapna are able to help customers create unique, meaningful gifts, gift hampers, and personalized items. Some of the unique gifts offered at Gifts by Sapna include: ring plates; personalised balloons; fresh flowers; jewellery; mugs; personalised plaques; and other quality products. Gifts by Sapna is an excellent place for special presents for all sorts of occasions such as birthdays, anniversaries, weddings, baby showers, Ramadan, Eid, Valentine’s Day, Father’s Day, Mother’s Day, graduations, and more. Gifts by Sapna is preparing to move to an even bigger location because of their ongoing success. Gifts by Sapna are proud to serve Bradford and the surrounding communities.

When the time came to choose this year’s recipient, Gifts by Sapna emerged as a noteworthy company in the gift shop sector. Their approachable team is well-regarded within the Bradford community, and positive reviews of Gifts by Sapna are abundant. Here are a few of the numerous positive testimonials penned by satisfied customers who were thoroughly impressed with the communication, products, and services offered by Gifts by Sapna. “Amazing customer service! I purchased a personalised flower box and a personalised balloon, it definitely exceeded my expectations and were loved by family! Definitely would be using their services again.” “I have visited many times and have always been happy with the service. I’m always greeted with respect and receive amazing customer service. The prices are very reasonable. Gift hampers are perfect, and made exactly as requested and there’s also a good variety of ready made hampers to pick up if in a rush.” “Been to the shop a number of times and bought a couple of times and on both occasions it’s been fantastic. It’s a family business with great customer service. They are very calm and willing to help in the best possible way. Definitely recommend.” “I recently purchased such an awesome gift for a colleague. One of those money shooting balloons and can I say it was absolutely worth it!!! Stunning colours and great quality not to mention my colleague loved it soooo much!!! The owner of the shop is literally the most beautiful and amazing person I ever met!! I couldn’t recommend gifts by Sapna enough!! If you want that wow factor gift with the most amazing customer service this is the place for you! Not to mention they have a wonderful collection of gifts in the shop for all occasions literally ready to take away. Thank you sooo much for your amazing service and my beautiful gift for my colleague. I will be back I promise!” The entire Gifts by Sapna team consistently exceed expectations by assisting each customer in finding an ideal gift for any occasion.

The Quality Business Awards recognizes businesses achieving an average quality score of 95% or higher throughout the preceding year. To be eligible, a business must garner outstanding customer reviews from at least three different platforms. Those upholding sterling reputations and track records over multiple years with minimal complaints receive high scores. Moreover, businesses that consistently engage with and respond to customer feedback are held in high esteem. Additionally, adherence to integrity, community involvement, and proactive efforts to reduce environmental impact are important criteria. Receiving a Quality Business Award shows a dedication to delivering superior products and exceptional customer service.

For more information about Gifts by Sapna, please visit the company’s Instagram account at [Gifts By Sapna (@giftsbysapna1) • Instagram photos and videos].

Contact:

Quality Business Awards

support@qualitybusinessawards.co.uk

Media Contact
Company Name: Gifts by Sapna
Email: Send Email
Country: United Kingdom
Website: https://www.instagram.com/giftsbysapna1/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Gifts by Sapna Wins the 2024 Quality Business Award for The Best Gift Shop in Bradford, UK

Top Realtor Agent in Bozeman, MT, Highlights the Importance of Professional Home Presentation for Online Listings

Sarah O’Neil, a well-known Bozeman, MT Realtor, emphasizes the crucial role of professional home presentation in today’s digital-first real estate market. At Sarah O’Neil Realty, the focus is not just on selling homes but on crafting an online presence that captivates and engages potential buyers from the first click.

Understanding the pivotal role of online listings in the home buying process, Sarah leverages her extensive interior design background to ensure each property is showcased to its fullest potential. “In the era of online home shopping, first impressions are formed long before a potential buyer steps through the front door. It’s essential that the online presentation is as compelling as the physical property,” Sarah explains.

With statistics showing that nearly 99% of millennials, who are currently the largest group of homebuyers, start their home search online, the impact of digital presentation is undeniable. Sarah’s strategy includes professional photography and virtual tours that highlight each home’s best features, ensuring that properties are not just seen but remembered.

As a real estate agent in Bozeman, MT, Sarah’s approach is detailed and client-focused. She assists sellers in preparing their homes for sale, advising on everything from decluttering to minor renovations that can significantly enhance a home’s visual appeal online. This meticulous attention to detail ensures that listings are not only attractive but also strategically positioned to attract the right audience.

“Effective online listings are the cornerstone of modern real estate marketing. They serve as the initial point of interaction with potential buyers and set the tone for everything that follows,” says Sarah. Her commitment to excellence in this area has established her as one of the top Realtor agents in Bozeman, MT, known for her innovative methods and successful outcomes. Her approach ensures that her clients, whether online or in-person, receive the highest level of service and support.

For those looking to sell a property in Bozeman, partnering with Sarah means working with a top real estate selling agent in Bozeman, MT who understands the nuances of both the physical and digital landscapes of real estate. To learn more, visit http://www.sarahoneilrealty.com/.

Media Contact
Company Name: Sarah O’Neil Realty | Real Estate Agent in Bozeman MT
Contact Person: Sarah O’Neil
Email: Send Email
Phone: +1 406-579-9836
Address:1001 West Oak St Bldg. C, Suite 111
City: Bozeman
State: Montana 59715
Country: United States
Website: http://www.sarahoneilrealty.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Top Realtor Agent in Bozeman, MT, Highlights the Importance of Professional Home Presentation for Online Listings